Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

The Evolution of beta-Blo… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The Evolution of beta-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)

Artikel i vetenskaplig tidskrift
Författare P. Joseph
Karl Swedberg
D. P. Leong
S. Yusuf
Publicerad i Journal of the American College of Cardiology
Volym 74
Nummer/häfte 5
Sidor 672-682
ISSN 0735-1097
Publiceringsår 2019
Publicerad vid Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 672-682
Språk en
Länkar dx.doi.org/10.1016/j.jacc.2019.04.0...
Ämnesord beta-blockers, coronary artery disease, heart failure, preserved ejection fraction, acute myocardial-infarction, low-income, countries, cardiovascular-disease, clinical-outcomes, middle-income, bucindolol, mortality, trial, carvedilol, Cardiovascular System & Cardiology
Ämneskategorier Kardiologi

Sammanfattning

As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of beta-adrenergic receptor blockers (beta-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting beta-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. beta-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of beta-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. (C) 2019 by the American College of Cardiology Foundation.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?